Previous close | 56.62 |
Open | 56.70 |
Bid | 57.41 x N/A |
Ask | 58.01 x N/A |
Day's range | 56.64 - 58.82 |
52-week range | 51.34 - 94.80 |
Volume | |
Avg. volume | 5 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MADISON, Wis., May 01, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences...
MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.